Challenge
A pharmaceutical company acquired a late-stage product with manufacturing variability and complex filing needs. After an FDA approvable letter identified more than one hundred deficiencies, teams committed to a twelve-month response schedule.
Response
PMO Partners coordinated eight functional teams through linked plans, structured decisions, and risk management. The program addressed manufacturing and analytical issues, accommodated an extended stability-testing requirement, and managed conversion to the Common Technical Document format alongside global submissions.
Outcome
The NDA was submitted and approved without delay, and the product launched within 48 hours of approval. The source calculated a $9.2 million net present value for avoided delays and reported $3.1 million in cost savings from timely activities and stronger-than-expected yields. The financial measures are distinct and should not be added as equivalent cash results.
An edited client story. Outcomes and figures describe the reported engagement, rather than a promise of results for another organization.